Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab Open Label Extension in Relapsing Multiple Sclerosis
NCT04130997Phase 3Active, not recruiting
- Sponsor
- TG Therapeutics, Inc.
- Start
- Nov 2019
- Primary completion
- May 2032
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of ublituximab in multiple sclerosis (MS), sponsored by TG Therapeutics, Inc.. Started Nov 2019; status: active, not recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04130997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130997.